Orphazyme A/S

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Orphazyme Announces Publication of 2022 Financial Results and Annual Report

Company announcement Orphazyme A/S No. 36/2022              www.orphazyme.com Company Registration No. 32266355

Orphazyme reports financial results in Interim Report First Half 2022

Orphazyme A/SCompany announcement No. 30/2022                                                                        Annual reportwww.orphazyme.com Company Registration No. 32266355

Orphazyme Announces Publication of 2021 Financial Results and Annual Report

KemPharm

Orphazyme A/SCompany announcement No. 29/2022                                                                        Inside information www.orphazyme.com Company Registration No. 32266355

Orphazyme completes sale of substantially all of its assets and business activities to KemPharm

Orphazyme A/S in restructuring Company announcement No. 24/2022Inside information www.orphazyme.com Company Registration No. 32266355

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

Orphazyme A/S in restructuring Company announcement No. 23/2022Inside information  www.orphazyme.com Company Registration No. 32266355

Orphazyme announces update on in-court restructuring proceedings

Orphazyme A/S (NASDAQ: ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA enables us to.

Orphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSs

After Orphazyme announced that it would withdraw the application for approval of its drug and delist its ADSs, ORPH stock is falling. The post Dear ORPH Stock Fans, Mark Your Calendars for March 31 appeared first on InvestorPlace.

Dear ORPH Stock Fans, Mark Your Calendars for March 31

Orphazyme A/S Company announcement No. 13/2022Inside information www.orphazyme.com Company Registration No. 32266355

Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C

Orphazyme A/S Company announcement No. 12/2022 www.orphazyme.com Company Registration No. 32266355

Orphazyme A/S has filed for voluntary delisting of ADSs

Orphazyme A/S Company announcement No. 11/2022 www.orphazyme.com Company Registration No. 32266355

Notice of in-court restructuring proceedings of Orphazyme A/S

The troubled biotech company's share price is up 40% despite plans to delist from the Nasdaq exchange and lay off 50% of its workers. The post Why Is Orphazyme (ORPH) Stock Up Today?

Why Is Orphazyme (ORPH) Stock Up Today?

Orphazyme A/S's (NASDAQ: ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-court restructuring will determine whether any operations can continue if the Company can raise any capital or if it is.

Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce

Orphazyme A/S Company announcement No. 10/2022Inside information www.orphazyme.com Company Registration No. 32266355

Commencement of in-court restructuring of Orphazyme A/S

Company announcement No. 08/2022 www.orphazyme.com Company Registration No. 32266355

Anders Vadsholt takes over as CEO of Orphazyme

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") announced update on the ongoing review of the Marketing Authorisation Application for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C ("NPC") by the Committee for Medici

CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

Orphazyme A/S (NASDAQ: ORPH) has been notified by the Committee for Medicinal Products for Human Use (CHMP) of a negative trend vote on arimoclomol application following an Oral Explanation. The application covers arimoclomol for Niemann-Pick disease type C (NPC), a rare genetic.

EMA's Advisory Committee Does Not Back Orphazyme's Arimoclomol Application

Orphazyme A/S Company ann ouncement No. 07/2022Inside information www.orphazyme.com Company Registration No. 32266355

Orphazyme announces update on regulatory review of arimoclomol in the European Union

Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.

Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare Drug

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted Orphazyme A/S's (NASDAQ: ORPH) ("Orphazyme") announced update on the process and anticipated timelines for resubmission of its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its investigational product candidate, arimoclomol, for the

CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

Castor Maritime Inc

Modular Medical

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 11th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for February 11th, 2022

Orphazyme A/S Investor n ews No. 02/2022 www.orphazyme.com Company Registration No. 32266355

Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States

Orphazyme A/S Investor News No. 01/2022 www.orphazyme.com Company Registration No. 32266355

Orphazyme to present additional data on arimoclomol's mechanism of action during 2022 Annual WORLDSymposium™

Orphazyme A/S Company announcement No. 03/2022Inside information www.orphazyme.com Company Registration No. 32266355

Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO

Orphazyme A/S (NASDAQ: ORPH) expects FY21 sales of DKK 35 million – DKK 37 million, compared to the previous guidance of DKK 30 million – DKK 40 million. It anticipates operating expenses of DKK 665 million – DKK 675 million, lower than the earlier outlook of DKK 700 million – DKK 720 million.

News for Orphazyme A/S Stock (ORPH)